aTyr Pharma, Inc. — Earnings Quality Grade C
ATYR · Healthcare
Some red flags
Screening Summary
Management Signals
Financial Trends
Revenue & Net Income ($B)
Margins (%)
18-Point Screening
Revenue Quality
Insufficient data
Insufficient data
Revenue -19.1%, CFFO 10.3%. Cash follows revenue
Expense Quality
No material inventory
CapEx growth 18.5% vs revenue -19.1%. Normal
Insufficient data
Insufficient data
Cash Flow Quality
CFFO/NI = 0.84. Profits backed by cash
FCF is negative ($-0.1B)
Accruals ratio = -13.0%. Low accruals
Cash $0.1B covers debt $0.0B
Balance Sheet Health
No goodwill. Clean balance sheet
Debt/EBITDA = -0.2x. Healthy
Other assets -21.0% vs revenue -19.1%. Normal
No write-off data
Acquisition Risk
FCF after acquisitions negative for 3 years
Small-cap context: A single acquisition on a small balance sheet can trip serial-acquirer logic.
No goodwill
Manipulation Score
Insufficient data
Portfolio monitoring
Monitor ATYR continuously
The full checks and model details are free to read. Use Watchlist to track your holdings; Pro adds automatic quarterly rescoring, risk-event email alerts, scans up to 50 tickers, and export workflows.
Altman Z-Score
Generated from public financial data using forensic accounting frameworks. Not investment advice. Data: Yahoo Finance · 2026-04-25